Covis Pharma to voluntarily withdraw preterm birth prevention drug from market

Covis Pharma to voluntarily withdraw preterm birth prevention drug from market

Covis Pharma Group has submitted a response to the presiding officer’s report on the FDA advisory committee hearing on the proposal to withdrawal approval for a preterm birth prevention drug, according to a press release.Currently, hydroxyprogesterone caproate injection (Makena, Covis Pharma) is the only FDA-approved treatment to reduce preterm birth risk in pregnant women who have